Ab­b­Vie backs an Ital­ian start­up fo­cused on au­toim­mune dis­eases; Bio­Th­eryX ad­vances AML drug with $35M D round

Italy’s En­thera Phar­ma­ceu­ti­cals has grabbed a €28 mil­lion launch round to back its work on, lay­ing brag­ging rights to the largest A round ever for an Ital­ian biotech.

The com­pa­ny is us­ing “non­tra­di­tion­al” tech to tar­get au­toim­mune dis­eases, look­ing to re-es­tab­lish stem cell ca­pa­bil­i­ties in type 1 di­a­betes and in­flam­ma­to­ry bow­el dis­ease.

Graziano Seghezzi, man­ag­ing part­ner of Sofinno­va Part­ners, co-seed­ed the com­pa­ny, with Ab­b­Vie step­ping in to help out. This is Ab­b­Vie’s first in­vest­ment in the Ital­ian biotech scene.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.